# Adversarial verification verdict — chromophobe_renal_cell_carcinoma.md

## 1. DOSE LEAK
None. Grepped the sidecar for any digit (`grep -n '[0-9]'`); the only hits are
"anti-PD1" (line 53, the "1" is part of the receptor name, not a dose) and
"12th ed" (line 103, edition number). No mg, mg/m2, AUC, %, or numbered
schedule anywhere in the clinical text.

## 2. UNGROUNDED CLAIMS
None found to be fabricated. Every specific claim checked traced to DeVita
12th ed, Ch. 43 (Cancer of the Kidney):

- Chromophobe RCC surgical framework (partial vs radical nephrectomy, thermal
  ablation, active surveillance) — matches DeVita's "Treatments for Localized
  Renal Cell Carcinoma" section headers (~150256-150278, Table 43.5).
- "Routine ipsilateral adrenalectomy is no longer performed unless there is
  direct invasion or a suspicious adrenal lesion" — near-verbatim match to
  DeVita lines 150266-150269 ("Removal of the ipsilateral adrenal gland is no
  longer recommended, unless there is suspicion of direct invasion... or a
  radiographically or clinically suspicious adrenal tumor").
- Adjuvant trial summary (VEGF-TKI trials + one mTOR trial enrolling
  non-clear-cell/chromophobe, mostly negative; the one positive DFS trial —
  S-TRAC — enrolled clear-cell-predominant disease only) — matches Table 43.7
  entries verbatim: ASSURE and SORCE explicitly list "Clear cell and
  non-clear cell RCC eligible" with negative DFS results; EVEREST (everolimus,
  the mTOR trial) also lists "Clear cell and non-clear cell RCC eligible";
  S-TRAC explicitly lists "Clear cell predominant histology eligible" with the
  one positive modest DFS result (lines 150882-151167). Minor imprecision:
  EVEREST's own result is listed as "Not reported" in this DeVita edition
  rather than explicitly negative, so folding it into "did not demonstrate a
  consistent benefit" slightly overstates what DeVita says about that one
  trial — not fabrication, but worth flagging as a small hedge issue.
- Everolimus activity "maintained independent of histology... stronger
  activity... specifically in chromophobe tumours than other non-clear-cell
  subtypes" — near word-for-word match to DeVita line 28028-28030
  ("Everolimus efficacy is maintained independent of the histology with
  seemingly stronger activity on chromophob non-clear cell RCC than other
  non-clear cell histology types").
- IO-combination as new standard of care, VEGF-TKI in refractory setting,
  mTOR pushed to third-line+, mTOR+VEGF-TKI combination signal for second
  line — matches DeVita lines 28031-28032 and 151979-151982 ("IO-based
  doublets are the standard of care initial therapy in advanced RCC, with
  generally single-agent VEGF TKI in the refractory setting") and the
  lenvatinib/pembrolizumab or cabozantinib/nivolumab first-line passage
  (~23483-23488). Sidecar correctly generalizes away from naming the specific
  drugs/trials (reasonable, avoids overclaiming chromophobe-specific data).
- Sarcomatoid dedifferentiation = worse prognosis — matches DeVita
  (~149138, 152799-152800, Table 43.6 VHR risk criteria).
- Birt-Hogg-Dube syndrome / FLCN / hereditary work-up section — matches
  DeVita's dedicated "Chromophobe Renal Cell Carcinoma / Birt-Hogg-Dube
  Syndrome" subsection nearly point for point (~150096-150118): autosomal
  dominant, fibrofolliculomas, pulmonary cysts, chromophobe/hybrid oncocytic
  histology association, FLCN mutations found in a minority of sporadic
  chromophobe cases.
- Follow-up extending to ~5 years with recurrences occurring after that point
  — matches DeVita line 150944 ("up to 30% recurrences occur after 5 years")
  and the AUA risk-stratified follow-up table (43.6); sidecar correctly
  withholds the specific "30%" number and the numbered follow-up schedule.
- No reliable chromophobe-specific systemic-therapy trial data — correctly
  and explicitly flagged by the sidecar itself as extrapolated; DeVita has no
  chromophobe-specific systemic trial arm, consistent with the draft agent's
  own disclosure.

No claim was found asserting a specific named first-line IO-combination
regimen, trial-level statistic, or adjuvant checkpoint-inhibitor use tied
specifically to chromophobe histology — consistent with the draft agent's
stated omissions, and consistent with what is actually in DeVita.

## 3. CITATION
Present: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles &
Practice of Oncology, 12th ed." (line 102-103). Name only, no page numbers. Correct format.

## 4. VERDICT: CLEAN (ready for R1)

One minor note for R1's attention (not a blocker): the adjuvant-trial
paragraph folds EVEREST (mTOR, mixed histology) into "did not demonstrate a
consistent... benefit" alongside ASSURE/SORCE, but DeVita lists EVEREST's own
DFS result as "Not reported" rather than explicitly negative. The overall
conclusion (no chromophobe-specific adjuvant benefit established) still
holds and is separately, explicitly stated by the sidecar as its own
sentence, so this is a hedge-precision nitpick, not a fabrication.
